Skip to main content

Advertisement

SpringerLink
Log in

Recent advances in therapy for gastrointestinal stromal tumors

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Sarcomas comprise less than 1% of all cancers. Gastrointestinal stromal tumor (GIST) is the most common form of sarcoma and can vary in size and clinical outcome from an incidental finding at operation to life-threatening metastatic disease. Surgery is the standard of care for primary disease, and the oral drug imatinib is the standard of care for metastatic disease. Sunitinib was approved in the United States in early 2006 for GIST that is refractory to imatinib. The pathology of GIST, surgical options for primary and metastatic disease, and findings leading to the use of imatinib and sunitinib for GIST are highlighted in this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2006. CA Cancer J Clin 2006, 56:106–130.

    Article  PubMed  Google Scholar 

  2. Nilsson B, Bumming P, Meis-Kindblom JM, et al.: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era—a population-based study in western Sweden. Cancer 2005, 103:821–829.

    Article  PubMed  Google Scholar 

  3. Fletcher CD, Berman JJ, Corless C, et al.: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002, 33:459–465.

    Article  PubMed  Google Scholar 

  4. Huizinga JD, Thuneberg L, Kluppel M, et al.: W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995, 373:347–349.

    Article  PubMed  CAS  Google Scholar 

  5. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577–580.

    Article  PubMed  CAS  Google Scholar 

  6. DeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51–58.

    Article  PubMed  CAS  Google Scholar 

  7. Ng EH, Pollock RE, Munsell MF, et al.: Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992, 215:68–77.

    Article  PubMed  CAS  Google Scholar 

  8. Ng EH, Pollock RE, Romsdahl MM: Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992, 69:1334–1341.

    Article  PubMed  CAS  Google Scholar 

  9. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G: Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002, 33:466–477.

    Article  PubMed  CAS  Google Scholar 

  10. DeMatteo RP, Antonescu CR, Chadaram V, et al.: Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. J Clin Oncol 2005, 23:9009.

    Google Scholar 

  11. American College of Surgeons: Z9001 Synopsis, vol. 2006. Synopsis of Z9001 adjuvant GIST study in PDF format; 2006. http://clinicaltrials.gov/ct/show/NCT00041197. Accessed 3/1/07.

  12. Eilber FC, Rosen G, Forscher C, et al.: Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 1999, 6:645–650.

    Article  PubMed  CAS  Google Scholar 

  13. Verweij J, Casali PG, Zalcberg J, et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127–1134.

    Article  PubMed  CAS  Google Scholar 

  14. Heinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21:4342–4349.

    Article  PubMed  CAS  Google Scholar 

  15. Corless CL, Schroeder A, Griffith D, et al.: PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 2005. 23:5357–5364.

    Article  PubMed  CAS  Google Scholar 

  16. Shankar S, vanSonnenberg E, Desai J, et al.: Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005, 235:892–898.

    Article  PubMed  Google Scholar 

  17. Antonescu CR, Besmer P, Guo T, et al.: Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005, 11:4182–4190.

    Article  PubMed  CAS  Google Scholar 

  18. Heinrich MC, Maki RG, Corless CL, et al.: Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol 2006, 24:9502.

    Google Scholar 

  19. Casali PG, Garrett CR, Blackstein ME, et al.: Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol 2006, 24:9513.

    Google Scholar 

  20. Heinrich MC, Maki RG, Corless CL, et al.: Correlation of KIT and PDGFRA Mutation Status with Sunitinib Malate (SU11248) Activity in Imatinib-resistant GIST. Presented at AACR Molecular Diagnostics in Cancer Therapeutic Development meeting. Chicago, IL; 2006.

  21. Blay JY, Bonvalot S, Casali P, et al.: Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann Oncol 2005, 16:566–578.

    Article  PubMed  Google Scholar 

  22. Wardelmann E, Merkelbach-Bruse S, Pauls K, et al.: Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006, 12:1743–1749.

    Article  PubMed  CAS  Google Scholar 

  23. Wardelmann E, Thomas N, Merkelbach-Bruse S, et al.: Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 2005, 6:249–251.

    Article  PubMed  CAS  Google Scholar 

  24. Fabian MA, Biggs WH III, Treiber DK, et al.: A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005, 23:329–336.

    Article  PubMed  CAS  Google Scholar 

  25. van Oosterom AT, Dumez H, Desai J, et al.: Combination signal transduction inhibition: A phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. J Clin Oncol 2004, 22:3002.

    Google Scholar 

  26. Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531–2541.

    Article  PubMed  CAS  Google Scholar 

  27. Nakatani H, Kobayashi M, Jin T, et al.: STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1. Cancer Sci 2005, 96:116–119.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Melanoma-Sarcoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10021-6007, USA

    Robert G. Maki MD, PhD

Authors
  1. Robert G. Maki MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Maki, R.G. Recent advances in therapy for gastrointestinal stromal tumors. Curr Oncol Rep 9, 165–169 (2007). https://doi.org/10.1007/s11912-007-0017-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-007-0017-0

Keywords

Search

Navigation